Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
about
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic ReviewProtecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.Effect of pregnancy on emtricitabine pharmacokinetics.Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.Evaluation of nevirapine dosing recommendations in HIV-infected children.Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.Obstetric Pharmacokinetic Dosing Studies are Urgently Needed.Pharmacokinetic optimization of antiretroviral therapy in pregnancy.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.
P2860
Q28109657-89AEFFE5-6AEB-490A-B76D-C4BB459EB09DQ34429204-3277610C-C766-4C44-B9E0-E5B2D20566A1Q35060812-46976062-6614-4B14-82BE-1F6E2CB31942Q35784583-A37999D8-1F4A-484C-84D7-B7048FCE2168Q35930696-87E8878B-963F-4E52-8BD0-6FE7FDCC19C2Q36276839-543324C3-B17D-4D08-9E17-5C71D3C543D8Q36676527-DC8E111F-47C4-4292-9822-2F316183A426Q36988025-08FDBAC5-9DBE-4EC8-93C0-D85F84551759Q37509532-F64A7CE3-42D7-4380-92FF-D17FBA2155ACQ37575742-050A4242-C92D-4452-9C82-F9D0C78CC53CQ38047214-F4470E07-B96B-45E0-BE3E-5EED0C3E817CQ38051400-7B7E1584-DB47-4D00-8ED1-86C8C3B98207Q38865904-69B27ABB-9A27-409D-9DE9-07A8C3B84E21Q47548999-311C4C8D-B0F9-4B3D-A4E8-0CF48267C037Q48072950-E4ACAC47-1105-475F-811E-A828C027C059
P2860
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chronic administration of nevi ...... pregnancy on pharmacokinetics.
@en
Chronic administration of nevi ...... pregnancy on pharmacokinetics.
@nl
type
label
Chronic administration of nevi ...... pregnancy on pharmacokinetics.
@en
Chronic administration of nevi ...... pregnancy on pharmacokinetics.
@nl
prefLabel
Chronic administration of nevi ...... pregnancy on pharmacokinetics.
@en
Chronic administration of nevi ...... pregnancy on pharmacokinetics.
@nl
P2093
P2860
P1433
P1476
Chronic administration of nevi ...... pregnancy on pharmacokinetics.
@en
P2093
E M Thorpe
E V Capparelli
P2860
P304
P356
10.1111/J.1468-1293.2008.00553.X
P577
2008-04-01T00:00:00Z